Loading...
Loading...
Curis, Inc.
, an oncology focused company developing novel,
targeted drug candidates for the treatment of human cancers, and Debiopharm
Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies
with a focus on the development of prescription drugs that target unmet
medical needs, including oncology as well as companion diagnostics, today
announced the presentation of data for Debio 0932 at the Annual Meeting of the
American Association for Cancer Research (AACR) that demonstrated synergy
between Debio 0932 and various standard of care (SOC) agents in multiple in
vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal
cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase
1/2 trial in combination with SOC agents in patients with advanced NSCLC and
in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in
advanced RCC patients.
Debiopharm Group(TM) Logo
In a high throughput combination screen performed with six different human
NSCLC cell lines, Debio 0932 demonstrated consistent synergy with microtubule
and mTOR/ Akt targeting agents across all six cell lines. Additionally, Debio
0932 also showed strong synergy with everolimus in multiple patient derived
and conventional RCC cell lines. Similar synergy and anti-tumor activity with
Debio 0932 in combination with these agents was also demonstrated in human
xenograft models of NSCLC and RCC.
"We are very encouraged by these preclinical data, which are the basis for the
ongoing trials in NSCLC and RCC with Debio 0932 in combination with respective
SOC agents," said Rolland-Yves Mauvernay, President and founder of Debiopharm
Group™.
"These preclinical combination treatment results with multiple agents provide
the path and strong rationale for clinical investigation of Debio 0932 in
combination with SOC therapies that may provide improved benefit for patients
with advanced lung and kidney cancers," said Ali Fattaey, Ph.D., President and
Chief Operating Officer of Curis.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in